Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 355

1.

Comparison between clinical diagnosis and CSF biomarkers of Alzheimer disease in elderly patients with late onset psychosis: Helsinki Old Age Psychosis Study (HOPS).

Seppälä TT, Louhija UM, Appelberg B, Herukka SK, Juva K.

Am J Geriatr Psychiatry. 2014 Sep;22(9):908-16. doi: 10.1016/j.jagp.2012.08.020. Epub 2013 Apr 15.

PMID:
23597931
2.

Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.

Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K.

Arch Neurol. 2001 Mar;58(3):373-9.

PMID:
11255440
3.

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P.

Arch Neurol. 1998 Jul;55(7):937-45.

PMID:
9678311
4.

Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.

Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L, Udompunthuruk S.

J Med Assoc Thai. 2011 Feb;94 Suppl 1:S77-83.

PMID:
21721431
5.

Cerebrospinal fluid biomarkers of Alzheimer's disease in Chinese patients: a pilot study.

Shea YF, Chu LW, Zhou L, Li WM, Lin OY, Chan MN, Xu A, Wong R, Ho TY, Liu KW, Ha J, Daniel TW, Song YQ, Lam KS.

Am J Alzheimers Dis Other Demen. 2013 Dec;28(8):769-75. doi: 10.1177/1533317513504615. Epub 2013 Oct 1.

PMID:
24085246
6.

Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort.

Schoonenboom NS, Reesink FE, Verwey NA, Kester MI, Teunissen CE, van de Ven PM, Pijnenburg YA, Blankenstein MA, Rozemuller AJ, Scheltens P, van der Flier WM.

Neurology. 2012 Jan 3;78(1):47-54. doi: 10.1212/WNL.0b013e31823ed0f0. Epub 2011 Dec 14.

PMID:
22170879
7.

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K.

JAMA. 2009 Jul 22;302(4):385-93. doi: 10.1001/jama.2009.1064.

PMID:
19622817
8.

Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.

Kang JH, Vanderstichele H, Trojanowski JQ, Shaw LM.

Methods. 2012 Apr;56(4):484-93. doi: 10.1016/j.ymeth.2012.03.023. Epub 2012 Apr 6. Review.

PMID:
22503777
9.

Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.

Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T.

Arch Neurol. 2009 Mar;66(3):382-9. doi: 10.1001/archneurol.2008.596.

PMID:
19273758
10.

Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.

Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Bergeson J, Manetti GJ, Zimmermann M, Tang B, Bartko JJ, Cohen RM.

JAMA. 2003 Apr 23-30;289(16):2094-103. Erratum in: JAMA. 2007 Oct 3;298(13):1516.

PMID:
12709467
11.

Analysis of combined CSF biomarkers in AD diagnosis.

De Riva V, Galloni E, Marcon M, Di Dionisio L, Deluca C, Meligrana L, Bolner A, Perini F.

Clin Lab. 2014;60(4):629-34.

PMID:
24779297
12.

CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings.

Seppälä TT, Nerg O, Koivisto AM, Rummukainen J, Puli L, Zetterberg H, Pyykkö OT, Helisalmi S, Alafuzoff I, Hiltunen M, Jääskeläinen JE, Rinne J, Soininen H, Leinonen V, Herukka SK.

Neurology. 2012 May 15;78(20):1568-75. doi: 10.1212/WNL.0b013e3182563bd0. Epub 2012 Apr 18.

PMID:
22517093
13.

Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.

Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O.

Arch Gen Psychiatry. 2012 Jan;69(1):98-106. doi: 10.1001/archgenpsychiatry.2011.155.

PMID:
22213792
14.

Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers.

Kester MI, Goos JD, Teunissen CE, Benedictus MR, Bouwman FH, Wattjes MP, Barkhof F, Scheltens P, van der Flier WM.

JAMA Neurol. 2014 Jul 1;71(7):855-62. doi: 10.1001/jamaneurol.2014.754.

PMID:
24818585
15.

Diagnostic Value of Cerebrospinal Fluid Biomarkers (Phospho-Tau181, total-Tau, Aβ42, and Aβ40) in Prodromal Stage of Alzheimer's Disease and Dementia with Lewy Bodies.

Bousiges O, Cretin B, Lavaux T, Philippi N, Jung B, Hezard S, Heitz C, Demuynck C, Gabel A, Martin-Hunyadi C, Blanc F.

J Alzheimers Dis. 2016;51(4):1069-83. doi: 10.3233/JAD-150731.

PMID:
26923009
16.

Comparison of two analytical platforms for the clinical qualification of Alzheimer's disease biomarkers in pathologically-confirmed dementia.

Le Bastard N, Coart E, Vanderstichele H, Vanmechelen E, Martin JJ, Engelborghs S.

J Alzheimers Dis. 2013;33(1):117-31. doi: 10.3233/JAD-2012-121246.

PMID:
22936010
17.

Cerebrospinal fluid Aβ1-40 improves differential dementia diagnosis in patients with intermediate P-tau181P levels.

Slaets S, Le Bastard N, Martin JJ, Sleegers K, Van Broeckhoven C, De Deyn PP, Engelborghs S.

J Alzheimers Dis. 2013;36(4):759-67. doi: 10.3233/JAD-130107.

PMID:
23666174
18.

Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.

Ibach B, Binder H, Dragon M, Poljansky S, Haen E, Schmitz E, Koch H, Putzhammer A, Kluenemann H, Wieland W, Hajak G.

Neurobiol Aging. 2006 Sep;27(9):1202-11. Epub 2005 Aug 8.

PMID:
16085339
19.

Added diagnostic value of CSF biomarkers in differential dementia diagnosis.

Le Bastard N, Martin JJ, Vanmechelen E, Vanderstichele H, De Deyn PP, Engelborghs S.

Neurobiol Aging. 2010 Nov;31(11):1867-76. doi: 10.1016/j.neurobiolaging.2008.10.017. Epub 2009 Jan 15.

PMID:
19150153
20.

CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies.

Luo X, Hou L, Shi H, Zhong X, Zhang Y, Zheng D, Tan Y, Hu G, Mu N, Chan J, Chen X, Fang Y, Wu F, He H, Ning Y.

J Neurochem. 2013 Dec;127(5):681-90. doi: 10.1111/jnc.12331. Epub 2013 Jun 26.

Supplemental Content

Support Center